Patent US5324643A successfully refreshed from Google Patents.
US5324643A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of conferring resistance to retroviral infection
Assignee: GREATBATCH-GEN AID Ltd A CORP OF NY
•
Filing: 1991-07-29
•
Granted: 1994-06-28
•
Expires: 2011-07-29
Abstract
Abstract In accordance with the present invention, disclosed is a method of conferring, upon a host cell, resistance to retroviral infection by interfering with one or more of the infection processes including retroviral replication and assembly into infective viral particles. The method involves introducing a vector into a host cell, wherein the vector comprises a polynucleotide which directs transcription, within the host cell, of RNA which is a) complementary or homologous, depending on the target region, to a nucleic acid sequence within one or more regions of the genome of the retrovirus; and b) is effective in inhibiting retroviral replication and/or interfering with assembly into viral particles when the host cell is infected. Also disclosed is a method of treatment using cells upon which resistance to infection has been conferred.
Inventors
- 👤 Wilson Greatbatch
- 👤 John C. Sanford
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 06:17
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; C07; C07K; C07K14/00; C07K14/005; C12N15/1132; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K48/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/13011; C12N2740/13022; C12N2740/13041; C12N2740/13043; C12N2740/15011; C12N2740/15022; C12N2740/16011; C12N2740/16041; C12N2740/16043
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
125 words
A method of conferring resistance to retroviral infection upon a host cell by inhibiting in the infection process at least one step of the process selected from the group consisting of retroviral replication, reverse transcription, and translation, said method comprising: Introduction into said host cell in vitro of a vector comprising a polynucleotide which is transcribed to RNA, within said host cell, said RNA is complementary to a nucleic acid sequence within at least one region within the genome of said retrovirus, wherein said region is an essential hybridization site within the retroviral genome selected from the group consisting of the 3'R-region, the primer binding (PBS) region, the AUG start codon region, and RNA splice sites; and wherein said retrovirus is feline leukemia virus (FeLV).
Claim 2
Independent Claim
125 words
A method of conferring resistance to retroviral infection upon a host cell by inhibiting in the infection process at least one step of the process selected from the group consisting of retroviral replication, reverse transcription, and translation, said method comprising: Introduction into said host cell in vitro of a vector comprising a polynucleotide which is transcribed to RNA, within said host cell, said RNA is complementary to a nucleic acid sequence within at least one region within the genome of said retrovirus, wherein said region is an essential hybridization site within the retroviral genome selected from the group consisting of the 3'R-region, the primer binding (PBS) region, the AUG start codon region, and RNA splice sites; and wherein said retrovirus is feline leukemia virus (FeLV).
Claim 3
Dependent Claim
12 words
The method of claim 1, wherein said polynucleotide is a synthetic polynucleotide.
Claim 4
Dependent Claim
10 words
The method of claim 1, wherein said polynucleotide is DNA.
Claim 5
Dependent Claim
24 words
The method of claim 1, wherein said vector is selected from the group consisting of a viral vector, a retroviral vector and a plasmid.
Claim 6
Dependent Claim
11 words
The method of claim 4, wherein said vector is a plasmid.
Claim 7
Dependent Claim
26 words
The method of claim 1, wherein said polynucleotide directs transcription of a single RNA which is complementary to the multiple hybridization sites within the retrovirus genome.
Claim 8
Dependent Claim
23 words
The method of claim 4, wherein said vector further comprises a first promoter which controls transcription of said RNA within said host cell.
Claim 9
Dependent Claim
25 words
The method of claim 4, wherein said vector further comprises a first terminator which controls termination of transcription of said RNA within said host cell.
Claim 10
Dependent Claim
17 words
The method of claim 4, wherein said vector further comprises a marker for selection of transformed cells.
Claim 11
Dependent Claim
23 words
The method of claim 7, wherein said polynucleotide further comprises a second promoter which controls transcription of said RNA within said host cell.
Claim 12
Dependent Claim
13 words
The method of claim 10, wherein said promoter is RNA Polymerase III promoter.
Claim 13
Dependent Claim
25 words
The method of claim 8, wherein said polynucleotide further comprises a second terminator which controls termination of transcription of said RNA within said host cell.
Claim 14
Dependent Claim
15 words
The method of claim 12, wherein said terminator is a RNA Polymerase III terminator sequence.
Claim 15
Dependent Claim
116 words
A nucleic acid construct conferring resistance to retroviral infection upon a host cell by inhibiting in the infection process at least one step of the process selected from the group consisting of retroviral replication, reverse transcription, and translation, said construct comprising a polynucleotide which when introduced by a vector into the host cell in vitro results in transcription of the polynucleotide into RNA complementary to the nucleic acid sequences within multiple regions within the genome of said retrovirus, wherein said regions are essential hybridization sites within the retroviral genome consisting of the 3'R-region, the primer binding (PBS) region, the AUG start codon region, and RNA splice sties of said retrovirus; and wherein said retrovirus is FeLV.
Claim 16
Dependent Claim
116 words
A nucleic acid construct conferring resistance to retroviral infection upon a host cell by inhibiting in the infection process at least one step of the process selected from the group consisting of retroviral replication, reverse transcription, and translation, said construct comprising a polynucleotide which when introduced by a vector into the host cell in vitro results in transcription of the polynucleotide into RNA complementary to the nucleic acid sequences within multiple regions within the genome of said retrovirus, wherein said regions are essential hybridization sites within the retroviral genome consisting of the 3'R-region, the primer binding (PBS) region, the AUG start codon region, and RNA splice sties of said retrovirus; and wherein said retrovirus is FeLV.
Claim 17
Dependent Claim
14 words
The nucleic acid construct of claim 14, wherein said polynucleotide is a synthetic polynucleotide.
Claim 18
Dependent Claim
12 words
The nucleic acid construct of claim 14, wherein said polynucleotide is DNA.
Claim 19
Dependent Claim
26 words
The nucleic acid construct of claim 14, wherein said vector is selected from the group consisting of a viral vector, a retroviral vector and a plasmid.
Claim 20
Dependent Claim
13 words
The nucleic acid construct of claim 17, wherein said vector is a plasmid.
Claim 21
Dependent Claim
35 words
The nucleic acid construct of claim 17, wherein said vector further comprises a first promoter which controls transcription of said RNA within said host cell, and a first terminator which controls termination of said transcription.
Claim 22
Dependent Claim
19 words
The nucleic acid construct of claim 17, wherein said vector further comprises a marker for selection of transformed cells.
Claim 23
Dependent Claim
24 words
The nucleic acid construct of claim 19, wherein said polynucleotide comprises a second promoter which controls transcription of said RNA within said host cell.
Claim 24
Dependent Claim
15 words
The nucleic acid construct of claim 21, wherein said promoter is RNA Polymerase III promoter.
Claim 25
Dependent Claim
26 words
The nucleic acid construct of claim 19, wherein said polynucleotide comprises a second terminator which controls termination of transcription of said RNA within said host cell.
Claim 26
Dependent Claim
17 words
The nucleic acid construct of claim 23, wherein said terminator is a RNA Polymerase III terminator sequence.
Claim 27
Dependent Claim
117 words
An RNA molecule, produced from the transcription of a polynucleotide of a vector which has been introduced into a host cell in vitro, said RNA molecule (a) confers resistance to retroviral infection upon a host cell by inhibiting in the infection process at least one step of the process selected from the group consisting of retroviral replication, reverse transcription, and translation; and (b) is complementary to the nucleic acid sequences within multiple regions within the genome of said retrovirus, wherein said regions are essential hybridization sties within the retroviral genome consisting of the 3'R-region, the primer binding (PBS) region, the AUG start codon region, and RNA splice sites of said retrovirus, and wherein said retrovirus is FeLV.
Claim 28
Dependent Claim
117 words
An RNA molecule, produced from the transcription of a polynucleotide of a vector which has been introduced into a host cell in vitro, said RNA molecule (a) confers resistance to retroviral infection upon a host cell by inhibiting in the infection process at least one step of the process selected from the group consisting of retroviral replication, reverse transcription, and translation; and (b) is complementary to the nucleic acid sequences within multiple regions within the genome of said retrovirus, wherein said regions are essential hybridization sties within the retroviral genome consisting of the 3'R-region, the primer binding (PBS) region, the AUG start codon region, and RNA splice sites of said retrovirus, and wherein said retrovirus is FeLV.
Claim 29
Dependent Claim
24 words
The RNA molecule of claim 25, wherein said vector further comprises a first promoter which controls transcription of said RNA within said host cell.
Claim 30
Dependent Claim
26 words
The RNA molecule of claim 25, wherein said vector further comprises a first terminator which controls termination of transcription of said RNA within said host cell.
Claim 31
Dependent Claim
18 words
The RNA molecule of claim 25, wherein said vector further comprises a marker for selection of transformed cells.
Claim 32
Dependent Claim
23 words
The RNA molecule of claim 26, wherein said polynucleotide comprises a second promoter which controls transcription of said RNA within said host cell.
Claim 33
Dependent Claim
14 words
The RNA molecule of claim 27, wherein said promoter is RNA Polymerase III promoter.
Claim 34
Dependent Claim
25 words
The RNA molecule of claim 27, wherein said polynucleotide comprises a second terminator which controls termination of transcription of said RNA within said host cell.
Claim 35
Dependent Claim
16 words
The RNA molecule of claim 31, wherein said terminator is a RNA Polymerase III terminator sequence.
Claim 36
Dependent Claim
9 words
A cell modified by the method of claim 1.
Claim 37
Dependent Claim
7 words
Progeny of the cell of claim 33.
References Cited (Backward Citations)
WO1987003451A1
Cited
US4806463A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-06-27 | 1997-12-27 | 1998-06-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-06-27 | 2001-12-27 | 2002-06-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-06-27 | 2005-12-27 | 2006-06-28 | $7700.00 | Window Closed / Lapsed |